|
Aquarius AI Inc. Announces the Acquisition of Jellyworks Inc.
|
|
Aquarius AI
|
Nov 02, 2022 05:15PM
|
|
Aquarius AI Inc. Announces the Acquisition of Jellyworks Inc.
|
|
Aquarius AI
|
Nov 02, 2022 05:15PM
|
|
Aquarius AI Inc. Announces the Appointment of Len Schmidt as Chief Financial Officer
|
|
Aquarius AI
|
Mar 08, 2022 09:00AM
|
|
Aquarius AI Inc. Announces Warrant Amendments
|
|
Aquarius AI
|
Jun 29, 2022 04:05PM
|
|
Aquarius AI Inc. Partners with Leading US Bitcoin Hashrate Management Company Luxor Technology Corporation
|
|
Aquarius AI
|
Oct 26, 2021 08:30AM
|
|
Aquarius AI Inc. Provides Update On the Filings of Its Audited Financial Statements and Related Management Cease Trade Order
|
|
Aquarius AI
|
May 30, 2022 04:01PM
|
|
As NTSB Calls for Passive Alcohol Detection for Drivers, SOBRsafe Offers Solution
|
|
SOBR Safe Inc.
|
Oct 03, 2022 08:00AM
|
|
Awakn Establishes Separate Preclinical and Clinical Expert Advisory Boards to Optimize Delivery of Its Expanding Development Pipeline
|
|
Awakn Life Sciences Corp.
|
Jul 07, 2021 08:15AM
|
|
Awakn Life Sciences Acquires Exclusive Rights to MDMA Research from Imperial College London
|
|
Awakn Life Sciences Corp.
|
Sep 23, 2021 08:01AM
|
|
Awakn Life Sciences Announces Closing of Acquisition of Leading Ketamine-Assisted Psychotherapy Clinic in Norway
|
|
Awakn Life Sciences Corp.
|
Oct 05, 2021 07:30AM
|
|
Awakn Life Sciences Announces Closing of Private Placement
|
|
Awakn Life Sciences Corp.
|
Mar 22, 2022 07:30AM
|
|
Awakn Life Sciences Announces DTC Eligibility
|
|
Awakn Life Sciences Corp.
|
Sep 02, 2021 07:30AM
|
|
Awakn Life Sciences Announces Its Second Location in the UK for "Awakn Clinics London", Providing Treatment to the Largest City in the UK
|
|
Awakn Life Sciences Corp.
|
Aug 04, 2021 10:06AM
|
|
Awakn Life Sciences Announces Positive Results from Phase II A/B Ketamine-Assisted Therapy for Treatment of Alcohol Use Disorder Trial
|
|
Awakn Life Sciences Corp.
|
Jan 11, 2022 07:30AM
|
|
Awakn Life Sciences Announces the Findings from the Phase II A/B Study Are to Be Published in the American Journal of Psychiatry
|
|
Awakn Life Sciences Corp.
|
Nov 04, 2021 07:40AM
|
|
Awakn Life Sciences Announces Voluntary Lock-up Agreement Extension with Management, Board of Directors and Key Shareholders
|
|
Awakn Life Sciences Corp.
|
Jan 04, 2022 08:28AM
|
|
Awakn Life Sciences Appoints Biotech and Investment Veteran Dennis Purcell as a Special Advisor to the CEO
|
|
Awakn Life Sciences Corp.
|
Jun 07, 2022 07:30AM
|
|
Awakn Life Sciences Appoints Former EVP & Chief Commercial Officer of Gilead Sciences, Paul Carter, as...
|
|
Awakn Life Sciences Corp.
|
Dec 14, 2021 07:30AM
|
|
Awakn Life Sciences Appoints Kevin Lorenz as U.S. Head of Commercial Development
|
|
Awakn Life Sciences Corp.
|
Mar 15, 2022 07:30AM
|
|
Awakn Life Sciences Appoints UK Leader in Addictions Psychiatry, Dr. Arun Dhandayudham, as Chief Medical Officer
|
|
Awakn Life Sciences Corp.
|
May 17, 2022 07:30AM
|
